Aeterna Zentaris (TSE:AEZS) Stock Price Up 1.1%

Aeterna Zentaris Inc. (TSE:AEZS) traded up 1.1% on Thursday . The stock traded as high as C$5.85 and last traded at C$5.56. 1,900 shares were traded during mid-day trading, an increase of 67% from the average session volume of 1,137 shares. The stock had previously closed at C$5.50.

Aeterna Zentaris Price Performance

The company has a debt-to-equity ratio of 1.80, a quick ratio of 9.37 and a current ratio of 5.94. The business has a 50 day simple moving average of C$7.29 and a 200-day simple moving average of C$6.67. The firm has a market cap of C$17.01 million, a price-to-earnings ratio of -1.75 and a beta of 2.26.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.